Trials / Unknown
UnknownNCT01608841
The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
The Role of Epidermal Growth Factor Receptor (EGFR) Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- Sponsor
- Taipei Veterans General Hospital, Taiwan · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the influence of epidermal growth factor receptor mutations on the efficacy of erlotinib and gemcitabine in metastatic pancreatic cancer.
Detailed description
The influence of EGFR mutations on the efficacy of treatment with and without erlotinib in metastatic pancreatic cancer is to be determined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib | Erlotinib 100 mg 1# PO qd till disease progression |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2012-05-31
- Last updated
- 2015-02-18
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01608841. Inclusion in this directory is not an endorsement.